Prior to last Thursday's transaction, YA II CD had held a 4.0% interest in ValiRx.
Shares were down 2.7% on Monday at
Mon, 19th Mar 2018 12:46
Prior to last Thursday's transaction, YA II CD had held a 4.0% interest in ValiRx.
Shares were down 2.7% on Monday at
LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.6%. The jet engine maker said it will cut
Read moreLONDON (Alliance News) - ValiRx PLC said Friday Nicholas Slater had almost doubled his stake in life science company, which focuses on cancer treatments, to 4.5% after a transaction on raised his
Read moreLONDON (Alliance News) - ValiRx PLC said Friday it has raised GBP950,000 through the issue of 47.5 million shares at 2.00 pence per share.The clinical stage biotechnology company's down
Read moreLONDON (Alliance News) - Biotechnology company ValiRx PLC said Wednesday its VAL201 compound has been granted a patent in the EU.This, it said, follows a US patent which was granted for a a
Read moreLONDON (Alliance News) - ValiRx PLC on Thursday said pre-clinical studies showed that its VAL101 compund has a potential to prevent cancer growth at cellular biochemical and genomic molecule is is
Read moreBUENOS AIRES, March 28 (Reuters) - Argentina's benchmark Merval stock index will shrink to 28 component companies in the second quarter, down from 31
Read moreBUENOS AIRES, March 28 (Reuters) - Argentina's benchmark Merval stock index will shrink to 28 component companies in the second quarter, down from 31
Read moreLONDON (Alliance News) - Biotechnology firm ValirX PLC said Tuesday its VAL201 therapeutic compound has been granted a patent in the US.VAL201, which is currently in is
Read more(ShareCast News) - Clinical stage biotechnology company ValiRx announced positive results in its VAL201 personalised Phase l/II prostate cancer study on Wednesday, adding that with accumulation of safety and tolerability data there is also evidence of disease stabilisation on CT imaging and reductio
Read more(ShareCast News) - Life science company focused on clinical stage cancer therapeutic development, ValiRx, updated the market on the clinical development of its novel cancer treatment drug, VAL401. The AIM-traded firm said ValiSeek, the joint venture between ValiRx and Tangent Reprofiling, was formed
Read more